The pleural diseases therapeutics market revenues is expected to rise steadily over the next decade, due to rising demand for treatment of various respiratory diseases such as lung cancer, tuberculosis and chronic obstructive pulmonary disease (COPD). Advances in therapy through things like minimally invasive procedures and targeted therapies promising more treatment options and better patient outcomes.
Additionally, the increasing geriatric population across the globe that is at a higher risk of pleural diseases is augmenting the demand for advanced treatment products. With greater awareness in the market and easier access to healthcare for patients, earlier diagnosis and treatment orders are helping drive growth within the market.
From 2025 to 2035, the market would realize a compound annual growth rate of 6.3%, which suggest that the total market size would be USD 10,405.4 Million by the end of forecast period, up from USD 5,648.4 Million in 2025.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 5,648.4 Million |
| Projected Market Size in 2035 | USD 10,405.4 Million |
| CAGR (2025 to 2035) | 6.3% |
Explore FMI!
Book a free demo
The pleural diseases therapeutics market in North America is driven by advanced healthcare infrastructure and the high prevalence of respiratory diseases. The region's focus on research and development, along with the adoption of innovative treatment approaches, contributes to market growth. Moreover, supportive government schemes and reimbursement policies encourage patients to receive these innovative treatments.
The pleural diseases therapeutics market in Europe is growing steadily owing to raising awareness regarding respiratory health and establishment of efficient healthcare policies. On the other hand, countries like Germany, France and UK are focusing on building healthcare infrastructure and encouraging early diagnosis and treatment of pleural diseases. Advancing the value of advanced therapeutics with an emphasis on outcomes and quality of life drives adoption in the region.
The Asia-Pacific region will register the fastest growth in the market, owing to the rising prevalence of respiratory ailments, escalating healthcare infrastructure, and increasing health care expenditure. Rising prevalence of. pleural diseases, rising disposable income and increasing access to affordable healthcare are some of the key factors driving the market growth in countries like China, Japan and India.
Moreover, increasing physical awareness programs and government initiatives to regulate respiratory diseases are driving the growth of the market in this region.
Delayed Diagnosis, Treatment Complexity, and Limited Awareness
The pleural diseases therapeutics market is poised to face several challenges owing to the need for more efficient surveillance and early detection of pleural disorders, particularly for conditions such as malignant pleural effusion (MPE), pleuritis and pleural mesothelioma. Therapeutic intervention is often delayed as many patients are just presenting in advanced symptoms.
Moreover, pleural disease management is often multimodal, including systemic medications, thoracentesis, pleurodesis or surgery, necessitating specialized care and incur high costs. Access to pulmonologists and thoracic specialists is limited in many areas, particularly low- and middle-income countries, with little awareness among primary care providers about the early signs of pleural ailments.
Advancements in Targeted Therapies, Imaging, and Outpatient Procedures
The market is growing despite such barriers, owing to the rising prevalence of pleural complications of lung cancer, increasing incidence of pneumonia associated with tuberculosis, and age-related respiratory diseases. Innovations in targeted biologics, anti-inflammatory agents, and immunotherapies are generating new therapeutic avenues especially for malignant pleural conditions.
The increased use of minimally invasive thoracic procedures, including indwelling pleural catheters and image-guided thoracentesis, has made treatment more accessible in outpatient environments. AI-assisted imaging diagnostics, early screening protocols and telemedicine consultations are improving early detection and follow-up care.
They will also be available in combination therapies geared towards individual patients, such as checkpoint inhibitors, PD-1/PD-L1 therapies among others in clinical trials targeting for example ultrahigh responders for pleural mesothelioma with novel chemotherapeutic delivery methods.
During the period from 2020 to 2024, the market was bolstered by the heightened awareness of respiratory diseases subsequent to the COVID-19 pandemic, along with the standardization of portable imaging and pleural fluid analysis in diagnostic settings. But healthcare resource constraints and suboptimal access to specialty care delayed treatment and prevented optimal outcomes.
By 2025-2035 the focus will be on integrated care models that combine diagnostics, remote monitoring, and immunotherapy-based regimens. Thus, pleural fluid cytology analysis using AI, next-generation imaging, and genomic profiling of pleural tumors will play important roles in the early diagnosis and personalized treatment. The increasing patient education, along with growth of outpatient thoracic centers, will increase compliance with therapeutic protocols.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Emphasis on supportive care access and treatment safety |
| Consumer Trends | Focused on relief of symptoms and fluid drainage |
| Industry Adoption | Use of inpatient pleurodesis and systemic anti-infective therapy |
| Supply Chain and Sourcing | Dependent on generic anti-inflammatory drugs and surgical consumables |
| Market Competition | Dominated by hospital-based pulmonology and thoracic surgery centers |
| Market Growth Drivers | Increased incidence of MPE, pneumonia, and TB complications |
| Sustainability and Environmental Impact | Low environmental concern in delivery models |
| Integration of Smart Technologies | Minimal integration in traditional settings |
| Advancements in Therapeutics | Relied on NSAIDs, antibiotics, and chemotherapy |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Implementation of accelerated approvals for biologics and digital diagnostics |
| Consumer Trends | Increasing demand for personalized immunotherapies and early-stage detection |
| Industry Adoption | Shift to ambulatory catheterization, smart monitoring, and outpatient management |
| Supply Chain and Sourcing | Growth in biologic pipelines, targeted drug delivery systems, and AI diagnostics |
| Market Competition | Entry of biotech innovators, digital health startups, and outpatient service chains |
| Market Growth Drivers | Accelerated by mesothelioma trials, lung cancer comorbidity care, and imaging tech integration |
| Sustainability and Environmental Impact | Growth of disposable device innovations and sustainable outpatient procedure kits |
| Integration of Smart Technologies | Use of remote symptom tracking, AI cytopathology, and predictive risk scoring tools |
| Advancements in Therapeutics | Innovation in targeted monoclonal antibodies, gene therapy vectors, and immune checkpoint inhibitors |
The United States market leads the pleural disease management segment with persistent advanced infrastructure with developed availability of thoracoscopic procedures, pleural biopsies, and catheter-based drainage systems. The increase in lung cancer and mesothelioma cases, coupled with high access to biologics is propelling innovation in targeted therapeutics and outpatient interventional care.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 6.4% |
Conversely, early management of pleural disorders is being facilitated by NHS-backed guidelines and centralized referral systems in the UK There is also growing use of ambulatory pleural services and portable ultrasound diagnostics by hospitals, enabling care to be performed closer to home in more community settings. Share: New Research Hubs Investing in Mesothelioma Trials and AI-Enhanced Cytology Platforms
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 6.2% |
Cities in Europe namely Germany, France, and Italy are progressively emphasizing advanced pleural therapeutics that will be part of overall oncology/respiratory care initiative of the country. Growth is fueled by increasing incidences of asbestos-related pleural mesothelioma and the use of multimodal palliative care protocols. Blockages are being opened with investments in cross-border telehealth, as well as early screening.
| Country | CAGR (2025 to 2035) |
|---|---|
| EU | 6.3% |
Market growth is also being buoyed by Japan's aging population and high rate of respiratory infections and malignancies. More utilization of minimally invasive pleural diagnostics, indwelling catheter systems, and combination chemotherapy for malignant effusions, particularly in tertiary medical centers.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.3% |
The quickly evolving healthcare system of South Korea is facilitating speedier access to digital chest imaging, pleural fluid cytopathology, and thoracentesis kits. The use of AI imaging and lung cancer diagnostics is being supported by the government, latching onto growing use of targeted drugs for pleural damage.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 6.4% |
Overall, the pleural diseases therapeutics market is gradually expanding due to an increasing focus on early diagnosis, proper treatment, and palliative care for pleural diseases such as pleural effusion, mesothelioma, and pneumothorax by healthcare systems across the world.
Chemotherapy and Hospital-based end-user settings dominate the market in available treatments with the increasing incidence of pleural cancers in developing countries creating an availability of advanced diagnostic and interventional infrastructure. These segments are connected to maximize patient outcomes with the continuous monitoring of supportive care and multidisciplinary expertise.
Pleural therapies are rapidly combining systemic treatment with image-guided procedures, respiratory rehabilitation, and targeted drug regimens. While rising awareness and early screening are becoming more popular, the role of hospitals and integrated cancer centres also increases in way of drug market sales.
| Treatment | Market Share (2025) |
|---|---|
| Chemotherapy | 58.2% |
The treatment of the pleural disease is mainly carried out through chemotherapy, particularly when malignancy is present, such as malignant pleural mesothelioma, metastatic lung cancers, and recurrent effusions. Its systemic mechanism enables oncologists to treat not only localized but also widespread disease, enhancing survival and symptom relief.
More advanced formulations, including platinum-based doublets and immune-oncology formulations, are further extending treatment options. Chemotherapy is used in combination with procedures such as pleurodesis or thoracentesis to keep fluid at bay and prevent re-occurrence.
Intrapleural chemotherapy administration enhances local control while restricting toxicity.Preventive methods including surgical procedures like bullectomy and decortication play an important role in managing pneumothorax or fibrothorax patients; chemotherapy is the most crucial modality in pleural malignancies proven by its versatile categorization, supported by clinical guidelines and its strong palliative effect.
| End Users | Market Share (2025) |
|---|---|
| Hospitals | 64.7% |
Because of the intricate and invasive nature of the treatment, monitoring, and surgical or emergency-intervention needs, the majority share of pleural diseases therapeutic care is attributed to hospital settings. Patients with pleural disorders often need multidisciplinary input from pulmonologists, thoracic surgeons, oncologists and radiologists all of whom are typically available in hospital settings.
Hospitals provide high-resolution imaging, thoracoscopy, and intrapleural therapy delivery. Inpatient management provides 24-hour observation for acute presentations including empyema or spontaneous pneumothorax. They also help with clinical trial enrollment and palliative care services, especially for patients with advanced mesothelioma.
Hospitals are still investing in respiratory therapy units, chemotherapy day-care centers and digital care platforms, which facilitate the delivery of care. Indeed, as the number of cancer specialty units and critical care departments within hospitals continues to expand world-wide, so too will their involvement in the management of pleural disease.
Even though specialty clinics cater to outpatient needs and post-operative consultations, hospitals have a dominant presence in the domain of initial diagnosis, acute care, and integrated therapeutic procedures, allowing them to take the pole position.
The pleural diseases therapeutics market is expected to gain significant revenue through oncology clinics, specialty care centers, and, hospitals dealing with pleural effusion, mesothelioma, pneumothorax, and empyema. Focus on targeted therapies, thoracic drainage devices, and biologics fuel innovation in personalized, minimally invasive treatment strategies Immune checkpoint inhibitors, intrapleural fibrinolytics, and catheter-based drug delivery are under investigation by multiple companies.
Innovators in biopharma and designers of medtech continue to heavily focus on enhanced patient survival outcomes, early intervention protocols and cross-disciplinary pulmonary-oncology integration.
Market Share Analysis by Key Players & Pleural Diseases Therapeutics Providers
| Company Name | Estimated Market Share (%) |
|---|---|
| AstraZeneca plc | 14-18% |
| Bristol-Myers Squibb | 12-16% |
| Becton, Dickinson and Company | 10-14% |
| Roche Holding AG (Genentech) | 8-12% |
| Rocket Medical plc | 6-9% |
| Other Therapeutics Providers | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| AstraZeneca plc | In 2024, expanded durvalumab trials for malignant pleural mesothelioma in combination with chemotherapy; in 2025, launched an AI platform to identify high-risk pleural metastasis in NSCLC patients. |
| Bristol-Myers Squibb | Broadened nivolumab + ipilimumab combo therapy access for pleural mesothelioma in 2024 under updated NCCN guidelines; in 2025, initiated Phase II studies on localized immunotherapy via pleural catheters. |
| Becton, Dickinson and Company | Released an upgraded tunneled pleural catheter system in 2024 for outpatient effusion management; in 2025, integrated antimicrobial coating and self-sealing valve into next-gen thoracic kits. |
| Roche Holding AG (Genentech) | Introduced biomarker-guided atezolizumab therapy for mesothelioma in 2024; in 2025, developed a companion diagnostic for PD-L1 expression in pleural fluid samples. |
| Rocket Medical plc | Launched a portable vacuum-assisted pleural drainage system in 2024; in 2025, rolled out remote monitoring-enabled drainage kits for home-based palliative care. |
Key Market Insights
AstraZeneca plc (14-18%)
AstraZeneca is leading pleural mesothelioma innovation through immuno-oncology and early detection platforms. Its 2024 to 2025 pipeline integrates AI diagnostics and immunotherapy to reshape thoracic cancer care.
Bristol-Myers Squibb (12-16%)
BMS expands its dual checkpoint inhibitor approach for malignant pleural conditions. Its 2025 focus on local delivery methods marks a strategic shift toward intrapleural immunomodulation.
Becton, Dickinson and Company (10-14%)
BD is at the forefront of minimally invasive thoracic care. The 2024 to 2025 catheter system upgrades improve infection prevention and enable long-term home drainage with ease of use.
Roche Holding AG (Genentech) (8-12%)
Roche drives biomarker-led pleural cancer therapeutics. Its 2025 diagnostic tool supports precision treatment using PD-L1 profiling, advancing the role of fluid-based oncology diagnostics.
Rocket Medical plc (6-9%)
Rocket Medical pioneer’s user-friendly pleural drainage technology. With 2025’s connected care rollout, the company addresses quality-of-life improvements in chronic effusion management.
Other Key Players (30- 40% Combined)
The overall market size for the pleural diseases therapeutics market was USD 5,648.4 Million in 2025.
The pleural diseases therapeutics market is expected to reach USD 10,405.4 Million in 2035.
The demand for pleural diseases therapeutics is rising due to the increasing prevalence of respiratory disorders and pleural cancers, advancements in treatment protocols, and rising hospital admissions for thoracic complications. Improved chemotherapy regimens and growing investment in hospital-based care infrastructure are further driving market growth.
The top 5 countries driving the development of the pleural diseases therapeutics market are the USA, China, Germany, Japan, and the UK.
Chemotherapy and hospital-based care are expected to command a significant share over the assessment period.
Cardiogenic Shock Treatment Market Analysis & Forecast for 2025 to 2035
The Metered Dose Inhalers Market is Segmented by Type, and End User from 2025 to 2035
The Staphylococcus Aureus Testing Market Is Segmented by Test Type, Application and End User from 2025 To 2035
The Dyslexia Treatments Market Is Segmented by Drug Type and Distribution Channel from 2025 to 2035
The Spinal Fusion Market is segmented by Product, Procedure and End User from 2025 to 2035
The Laser Therapy Devices Market is segmented by Device Type and End User from 2025 to 2035
Pleural Diseases Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
